P0668 : On-treatment HBsAg kinetics to predict long-term HDV RNA response to peg-IFNa treatment of hepatitis delta

Wöbse, M.; Hardtke, Svenja; Ernst, Stefanie; Benjamin, Ho Chee Meng; Bremer, Birgit; Keskın, Onur; Koch, Alexandra; Manns, M.P.; Wedemeyer, Heiner; Yurdaydın, Cihan

doi:10.1016/s0168-8278(15)30872-2

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Negative predictive values for virological non‐response 24 weeks after end of the treatment for a 1 log HDV RNA decline were low for treatment weeks 4 to 12 but increased for treatment week 24 and 48 with 85% and 95% respectively. These ‘late’ on‐treatment HDV RNA kinetics support the idea of identifying patients not benefiting from prolonged treatment duration, whereas early HDV RNA kinetics did not help differentiating future treatment responders from non‐responders 73,74 . Still, more studies are needed to confirm these findings.…”

Section: Predictors Of Response To Interferon‐based Antiviral Treatme...mentioning

confidence: 82%

“…These 'late' on-treatment HDV RNA kinetics support the idea of identifying patients not benefiting from prolonged treatment duration, whereas early HDV RNA kinetics did not help differentiating future treatment responders from non-responders. 73,74 Still, more studies are needed to confirm these findings. At this stage, HDV RNA should be determined at least every 12 weeks during treatment and patients with no HDV decline until week 24 have a low chance to show a durable off-treatment response even though some patients may still respond between week 24 and 48.…”

Section: Pred I C Tor S Of Re S P On S E To Interferon -Ba S Ed Antiv...mentioning

confidence: 98%

“…No clear stopping rules established, but low chances of off-treatment response if no HDV RNA decline until treatment week 24 [73][74][75].…”

Section: Safe T Y Of Interferon -Ba S Ed Antivir Al Tre Atment In Hep...mentioning

confidence: 99%

See 2 more Smart Citations

Interferon‐based treatment of chronic hepatitis D

Sandmann

Wedemeyer

2022

Liver International

View full text Add to dashboard Cite

Treatment of hepatitis D virus (HDV) infection has been based on the administration of interferon‐alfa for more than three decades. First studies to treat HDV‐infected patients with type 1 interferons were already performed in the 1980s. Several smaller trials and case series were reported thereafter. During the mid 2000s the use of pegylated interferons for hepatitis D was established. Since then, additional trials were performed in different countries exploring strategies to personalize treatment including extended treatment durations. The overall findings were that about one‐quarter to one‐third of patients benefit from interferon treatment with persistent suppression of HDV replication. However, only few patients achieve also functional cure of hepatitis B with HBsAg loss. Importantly, several studies indicate that successful interferon treatment is associated with improved clinical long‐term outcomes. Still, only a proportion of patients with hepatitis D can be treated with interferons. Even though alternative treatments are currently developed, it is likely that pegylated interferon‐alfa will still have an important role in the management of hepatitis D – either alone or in combination. Therefore, better biomarkers are needed to select patients with a high likelihood to benefit from interferon‐based treatments. In this review we are discussing basic principles of mode of action of interferon alpha against HDV, summarize previous data on interferon treatment of hepatitis D and give an outlook on potential combinations with novel drugs currently in development.

show abstract

Section: Predictors Of Response To Interferon‐based Antiviral Treatme...mentioning

confidence: 82%

Section: Pred I C Tor S Of Re S P On S E To Interferon -Ba S Ed Antiv...mentioning

confidence: 98%

See 1 more Smart Citation

Interferon‐based treatment of chronic hepatitis D

Sandmann

Wedemeyer

2022

Liver International

View full text Add to dashboard Cite

show abstract

“…Results are disappointing (34% and 42% of undetectable HDV RNA at 48 weeks, respectively and 47% and 33% at the end of treatment, respectively) with high relapse rate after end of treatment [16,48].…”

Section: Chronic B-delta Hepatitismentioning

confidence: 99%

“…A dose-study to evaluate the virological impact, with a boost with ritonavir (100 mg) or with PEG-alpha2a at 1 and 2 months has been reported [53]. Results were compared to the proof-of-concept study results (lonafarnib alone) [50] and to the HIDIT-2 [48] PEG+TDF results. The boost with ritonavir 100 mg or the combination with PEG-alpha-2a 180 µg/week improved the antiviral efficacy with a viral load decrease of 2 log and reduced digestive side effects [53].…”

Section: Chronic B-delta Hepatitismentioning

confidence: 99%

Hepatitis Delta Virus: Epidemiology, Natural Course and Treatment

Sultanik¹,

Pol²

2016

J Infect Dis Ther

View full text Add to dashboard Cite

The hepatitis delta virus (HDV) is a defective hepatotropic virus that affects only patients with hepatitis B virus (HBV) infection. These 2 viruses share the same routes of transmission (parenteral, sexual, and mother to child). The hepatitis delta virus infection may result in acute hepatitis, including fulminant presentation or spontaneously resolving infection, and chronic infection. The prognosis depends on the chronology of the 2 infections, co-infection (higher risk of fulminant hepatitis) or super-infection (frequent evolution to chronicity). The harmfull impact of HIVassociated infection is today debated even if HDV antibodies are present in 12% and 4% of HIV/HBV co-infected and HBV-mono-infected patients respectively. HDV may be treated by interferon, the unique treatment, but relapse is observed in 50% of cases after discontinuation of therapy: only 25% of treated patients achieved a sustained virologic response. Entry HBV/HDV inhibitors (Myrcludex) and prenylation inhibitors are awaited encouraging progress in treating HDV infection. The treatment is recommended in patients with significant fibrosis; viral suppression may result in fibrosis stabilization or reversal which may be also observed in the absence of complete viral eradication. The prevention of hepatitis delta virus infection is based on hepatitis B virus vaccination

show abstract

P0668 : On-treatment HBsAg kinetics to predict long-term HDV RNA response to peg-IFNa treatment of hepatitis delta

Cited by 2 publications

References 0 publications

Interferon‐based treatment of chronic hepatitis D

Interferon‐based treatment of chronic hepatitis D

Hepatitis Delta Virus: Epidemiology, Natural Course and Treatment

Contact Info

Product

Resources

About